Marc Goodman

Alzheimer's Progression Slowed Down By Biogen's New Drug In Late-Stage Study: Analyst Sees 25% Upside For Stock

Biohaven Rallies On Preliminary Nurtec Revenue Numbers: What Investors Need To Know

5 Biogen Analysts On FDA Approval Of Alzheimer's Drug Aduhelm, Broad Label, Pricing

Biohaven Rallies On Preliminary Nurtec Revenue Numbers: What Investors Need To Know

5 Biogen Analysts On FDA Approval Of Alzheimer's Drug Aduhelm, Broad Label, Pricing

After FDA Rejects Acadia Dementia Drug, Analysts Lament Lack Of Near-term Stock Drivers

Why This Biogen Analyst Says The FDA Could Still Approve Aducanumab

After FDA Rejects Acadia Dementia Drug, Analysts Lament Lack Of Near-term Stock Drivers

Why This Biogen Analyst Says The FDA Could Still Approve Aducanumab

Why Biogen's Fortunes Hinge On Aducanumab Approval

Why Marinus Pharma Shares Are Rocketing Higher

Marc Goodman Recent News

Biogen Soars As FDA Accepts Alzheimer's Drug For Review In 'Next Stage Of Aducanumab Saga'

Biogen Inc's (NASDAQ: BIIB) investigational Alzheimer's drug aducanumab — a drug for which the company halted studies at one point last year — could finally see the light of day.

Leerink Out Bullish On GW Pharma: 4 Reasons Why

Mallinckrodt Bull Turns Bear, Slashes Price Target By 66%

A Preview Of Next Week's Blue-Chip Earnings

UBS Downgraded AbbVie Shares; Here's What Changed Analysts' View

A Look At Teva's Paragard IUD Asset Sale To Cooper Companies, From Both Sides

Teva Loses Another Bull; Credit Suisse Downgrades

Earnings Watch: Apple, Tesla, Pfizer, Activision-Blizzard On Tap For Next Week

Intense Competition Pressures Eli Lilly, Leerink Downgrades

Analyst: Mallinckrodt Investors Seem To Be Pricing In Extreme Issues For Acthar

UBS Likes The Tune Of Jazz Pharma's Settlement With Hikma

Aside From The Recent Drug Failure, What Else Is Happening With Eli Lilly?

Near-Term Headwinds And Long-Term Promise For Gilead Sciences

Allergan Again A Core Holding At UBS

UBS Suspends Coverage Of Valeant Over Lack of Transparency

Some On Wall Street Still Back Valeant

Valeant's New-Old CEO: What To Know

These Four Analysts Remain Bullish On Valeant

UBS On Bristol-Myers Squibb: 'We Like This Opportunity Right Here Right Now'

Jazz Pharma Still Loved At UBS, Firm Hikes Price Target To $210

UBS Reviews ASCO, Notes Weekend Data Points From 2 Companies

UBS Says Impax 'Ahead Of Itself,' Downgrades To Sell

UBS Thinks AbbVie's Valuation Is 'Interesting'